Peer-influenced content. Sources you trust. No registration required. This is HCN.
Already approved to treat ovarian cancer, Rubraca (rucaparib) has been granted accelerated approval as the first PARP inhibitor to treat certain patients with prostate cancer, offering a completely new approach for physicians.
Hematology May 25th 2020
JAMA Network
A comprehensive guide from the American Medical Association (AMA), which includes information for those who want to support communities severely impacted by COVID-19, including the how and where to volunteer and all things to consider.
Allergy & Immunology April 13th 2020
Annals of Internal Medicine
Data to support the use of hydroxychloroquine (HCQ) and chloroquine (CQ) for COVID-19 are limited and inconclusive; this article from the American College of Physicians (ACP) discusses the facts to arm yourself with the proper information.
The New England Journal of Medicine
NEJM explores the question: Are we, in fact, what we eat? Can the periodic flipping of a “metabolic switch” truly help patients?
Allergy & Immunology March 16th 2020
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH